Fennec Pharmaceuticals stock
FENCNASDAQFennec Pharmaceuticals Inc., HealthcareISIN CA31447P1009
52Score 52 out of 100, Neutral
Price and trend
75 / 100
Price history
+40% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 17% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 58).
The price is 15% below its 52-week high. Largest decline in 9 years: 77% (April 2018 to June 2019).
Chart figures for advanced users
- SMA 50$10.66
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$9.33
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)58
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.77
- The lowest closing price of the last twelve months.
- Resistance$12.78
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Fennec Pharmaceuticals Inc. belongs to the Biotechnology industry (United States) and, with a market value of $382.23M, is number 272 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $44.64M (down 6.1% year on year) and a loss of $9.74M.
- For fiscal 2026, analysts expect on average revenue of $72.48M (up 62.4%) and adjusted earnings per share of $0.28.
Show more
- MEQIRI Score 52 out of 100 (Neutral): rank 368 of 714 in Healthcare, median 53.
- Our model puts fair value at $41.66, with the price 74% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 207.5% a year since 2022, Biotechnology median 19.7%.Growth 70
- More cash than debtCash $36.72M, financial debt $0 (fiscal 2025).Stability 56
Weaknesses
- Loss-makingLoss of $3.25M over the last 12 months.Fundamentals 17
- DilutionShare count up 21% since 2020.Capital allocation 18
- Negative free cash flowFree cash flow −$2.04M over the last 12 months.Fundamentals 17
Its standout strengths are valuation and momentum, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 51 to 52.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
Valuation
Valuation signal
Possible value trapClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $27.77 and expensive above $83.32 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 9.2%. At 10.2% the fair value would be $34.49, at 8.2% it would be $52.13.
Possible value trap: looks cheap, but weak balance sheet.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 77.8% on the twelve months before. Revenue has grown strongly since 2022, at around 208% per year. From 2022 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 92%, operating −14%, net −22%. Last 12 months: net −5%. From 2022 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
Fiscal 2025No financial debt is reported on the balance sheet.
Earnings
- Next earnings
- 23 Mar 2027in 131 days
- Last reported
- 12 Nov 2026EPS reported $0.12 (expected $0.10)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 4.2% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.28+0.2%
- Revenue
- $72.48M−0.1%
- Earnings per share
- $0.90−4.2%
- Revenue
- $102.22M−0.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $1.6M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Brughera Marco MariaSale
15 Sept 2026, Board
- Shares
- 15,545
- Price
- $10.29
- Value
- $159,958
- Raykov RostySale
1 Sept 2026, Board
- Shares
- 10,000
- Price
- $12.11
- Value
- $121,100
- Sayad Pierre SargisSale
31 Aug 2026, Chief Medical Officer
- Shares
- 12,000
- Price
- $12.18
- Value
- $146,160
Show 4 more
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Fennec Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 52
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- AlectorALEC $391.55M71
- ProKidneyPROK $379.97M27
- C4 TherapeuticsCCCC $379.51M35
- AltimmuneALT $375.42M25
- Sagimet BiosciencesSGMT $371.76M46
- Editas MedicineEDIT $365.52M28
- PepGenPEPG $363.83M43
- Orchestra BioMed HoldingsOBIO $361.23M49
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 10 Nov 2026, previously Weak
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.